BRAF Inhibitor
Information
- Drug Name
- BRAF Inhibitor
- Description
- Entry(CIViC)
- 5
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| melanoma |
BRAF p.Val640Asp (p.V640D) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Asp (p.V640D) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 31580757 | Detail |
| melanoma |
BRAF p.Val640Asp (p.V640D) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Asp (p.V640D) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 31580757 | Detail |
| melanoma | BRAF APC BRAF APC | B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 31580757 | Detail |
| melanoma | BRAF G469 BRAF G469 | B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 31580757 | Detail |
| melanoma | BRAF A598V BRAF A598V | C |
Predictive
|
Does Not Support
|
Sensitivity/Response | Somatic | 3 | 31580757 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| In a retrospective study from 20 institutes in 4 c... | BRAF |
BRAF p.Val640Asp (p.V640D) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Asp (p.V640D) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
Sensitivity | true | CIViC Evidence | detail |
| In a retrospective study from 20 institutes in 4 c... | BRAF |
BRAF p.Val640Asp (p.V640D) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Asp (p.V640D) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
Sensitivity | true | CIViC Evidence | detail |
| In a retrospective study from 20 institutes in 4 c... | BRAF | BRAF APC BRAF APC | Sensitivity | true | CIViC Evidence | detail |
| In a retrospective study from 20 institutes in 4 c... | BRAF | BRAF G469 BRAF G469 | Sensitivity | true | CIViC Evidence | detail |
| In a retrospective study from 20 institutes in 4 c... | BRAF | BRAF A598V BRAF A598V | Sensitivity | false | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02382549 | Terminated | Early Phase 1 | A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib | April 2016 | February 28, 2022 |
| NCT05080361 | Unknown status | Rechallenge of BRAF +/- MEK Inhibitors Following an Adverse Event in Patients With Cancer | January 1, 2011 | December 1, 2021 |